Cargando…
Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities
Recently, red blood cell-derived extracellular vesicles (RBCEVs) have attracted attention for clinical applications because of their safety and biocompatibility. RBCEVs can escape macrophages through the binding of CD47 to inhibitory receptor signal regulatory protein α. Furthermore, genetic materia...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739511/ https://www.ncbi.nlm.nih.gov/pubmed/35004730 http://dx.doi.org/10.3389/fmed.2021.761362 |
_version_ | 1784629115450556416 |
---|---|
author | Chiangjong, Wararat Netsirisawan, Pukkavadee Hongeng, Suradej Chutipongtanate, Somchai |
author_facet | Chiangjong, Wararat Netsirisawan, Pukkavadee Hongeng, Suradej Chutipongtanate, Somchai |
author_sort | Chiangjong, Wararat |
collection | PubMed |
description | Recently, red blood cell-derived extracellular vesicles (RBCEVs) have attracted attention for clinical applications because of their safety and biocompatibility. RBCEVs can escape macrophages through the binding of CD47 to inhibitory receptor signal regulatory protein α. Furthermore, genetic materials such as siRNA, miRNA, mRNA, or single-stranded RNA can be encapsulated within RBCEVs and then released into target cells for precise treatment. However, their side effects, half-lives, target cell specificity, and limited large-scale production under good manufacturing practice remain challenging. In this review, we summarized the biogenesis and composition of RBCEVs, discussed the advantages and disadvantages of RBCEVs for drug delivery compared with synthetic nanovesicles and non-red blood cell-derived EVs, and provided perspectives for overcoming current limitations to the use of RBCEVs for clinical applications. |
format | Online Article Text |
id | pubmed-8739511 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87395112022-01-08 Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities Chiangjong, Wararat Netsirisawan, Pukkavadee Hongeng, Suradej Chutipongtanate, Somchai Front Med (Lausanne) Medicine Recently, red blood cell-derived extracellular vesicles (RBCEVs) have attracted attention for clinical applications because of their safety and biocompatibility. RBCEVs can escape macrophages through the binding of CD47 to inhibitory receptor signal regulatory protein α. Furthermore, genetic materials such as siRNA, miRNA, mRNA, or single-stranded RNA can be encapsulated within RBCEVs and then released into target cells for precise treatment. However, their side effects, half-lives, target cell specificity, and limited large-scale production under good manufacturing practice remain challenging. In this review, we summarized the biogenesis and composition of RBCEVs, discussed the advantages and disadvantages of RBCEVs for drug delivery compared with synthetic nanovesicles and non-red blood cell-derived EVs, and provided perspectives for overcoming current limitations to the use of RBCEVs for clinical applications. Frontiers Media S.A. 2021-12-24 /pmc/articles/PMC8739511/ /pubmed/35004730 http://dx.doi.org/10.3389/fmed.2021.761362 Text en Copyright © 2021 Chiangjong, Netsirisawan, Hongeng and Chutipongtanate. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Chiangjong, Wararat Netsirisawan, Pukkavadee Hongeng, Suradej Chutipongtanate, Somchai Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities |
title | Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities |
title_full | Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities |
title_fullStr | Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities |
title_full_unstemmed | Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities |
title_short | Red Blood Cell Extracellular Vesicle-Based Drug Delivery: Challenges and Opportunities |
title_sort | red blood cell extracellular vesicle-based drug delivery: challenges and opportunities |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739511/ https://www.ncbi.nlm.nih.gov/pubmed/35004730 http://dx.doi.org/10.3389/fmed.2021.761362 |
work_keys_str_mv | AT chiangjongwararat redbloodcellextracellularvesiclebaseddrugdeliverychallengesandopportunities AT netsirisawanpukkavadee redbloodcellextracellularvesiclebaseddrugdeliverychallengesandopportunities AT hongengsuradej redbloodcellextracellularvesiclebaseddrugdeliverychallengesandopportunities AT chutipongtanatesomchai redbloodcellextracellularvesiclebaseddrugdeliverychallengesandopportunities |